Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractWe investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58–0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34–0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55–0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65–0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.
All Author(s) ListRachel Woodford, Yanni Loh, Joanna Lee, Wendy Cooper, Ian Marschner, Craig R Lewis, Michael Millward, Sally Lord, Richard J Gralla, James C-H Yang, Tony Mok, Chee K Lee
Journal nameFuture Oncology
Year2019
Month7
Volume Number15
Issue Number20
Pages2371 - 2383
ISSN1479-6694
eISSN1744-8301
LanguagesEnglish-United Kingdom
KeywordsPD-L1, non-small-cell lung cancer

Last updated on 2020-09-07 at 03:15